Matches in SemOpenAlex for { <https://semopenalex.org/work/W2340414627> ?p ?o ?g. }
Showing items 1 to 93 of
93
with 100 items per page.
- W2340414627 endingPage "5527" @default.
- W2340414627 startingPage "5527" @default.
- W2340414627 abstract "5527 Background: Taxane-based concurrent chemoradiation (CCR) for head and neck cancers has proven feasible and has a favorable toxicity profile compared to concurrent cisplatin and radiation. This phase II multi-institutional trial evaluates taxane-based induction chemotherapy followed by CCR for organ preservation in resectable Stage III/IV L and OP patients. Methods: Eligibility: Resectable stage T2N+, or T3-T4N0–3M0 biopsy-proven squamous Ca, age ≥18, PS 0–2, good organ function, and no prior chemotherapy or radiation. Treatment: induction paclitaxel (P) 175 mg/m 2 and carboplatin (C) AUC 6 for 2 cycles q21d followed by concurrent P 30 mg/m 2 q7d with 70 Gy if no evidence of progression. Weekly epoetin alpha 40kU was used if Hgb ≤15 (male) or ≤14 (female). The primary endpoint is organ preservation (freedom from salvage surgery with preserved speech and swallowing). Results: 105/111 pts (69 OP, 36 larynx) were eligible. Median FU is 33 months. No grade 5 toxicities occurred. 94% received full dose RT and 91% received ≥5 cycles of concurrent paclitaxel. At one year post-treatment, 13 (12%) patients required salvage surgery at the primary site (7-L, 6-OP), and 6 pts (6%) progressed and died (3-L, 3-OP). 1 pt (1%) died without progression and 85 pts (81%) are alive without progression (25-L, 60-OP). 12 pts (10%) have developed distant mets (6-L, 6-OP). 1-yr and 2-yr PFS for all pts is 77% and 64%. 12/69 OP and 9/36 L pts have died of disease. 1-yr event-free survival (EFS = no salvage surgery, recurrence or death) is 72% (77%-OP, 64%-L), and 2-yr EFS is 57% (68%-OP, 34%-L) (p = 0.02). 1-yr OS is 93%, 2-yr OS is 74% (OP vs. L p = 0.11). Conclusions: This regimen is well tolerated and is feasible in a multi-institutional setting. EFS with this regimen is lower than expected in larynx patients. The benefit of induction chemotherapy in this setting remains unproven but does not preclude CCR delivery. Funded, in part, by Bristol-Myers Squibb. [Table: see text]" @default.
- W2340414627 created "2016-06-24" @default.
- W2340414627 creator A5006101210 @default.
- W2340414627 creator A5017367541 @default.
- W2340414627 creator A5031390646 @default.
- W2340414627 creator A5034392417 @default.
- W2340414627 creator A5037781025 @default.
- W2340414627 creator A5045462759 @default.
- W2340414627 creator A5048060803 @default.
- W2340414627 creator A5058702476 @default.
- W2340414627 creator A5063957223 @default.
- W2340414627 creator A5087316611 @default.
- W2340414627 date "2006-06-20" @default.
- W2340414627 modified "2023-10-18" @default.
- W2340414627 title "Locally advanced resectable larynx (L) or oropharynx (OP) cancer: Updated results of organ preservation trial ECOG 2399" @default.
- W2340414627 doi "https://doi.org/10.1200/jco.2006.24.18_suppl.5527" @default.
- W2340414627 hasPublicationYear "2006" @default.
- W2340414627 type Work @default.
- W2340414627 sameAs 2340414627 @default.
- W2340414627 citedByCount "5" @default.
- W2340414627 countsByYear W23404146272015 @default.
- W2340414627 countsByYear W23404146272018 @default.
- W2340414627 countsByYear W23404146272023 @default.
- W2340414627 crossrefType "journal-article" @default.
- W2340414627 hasAuthorship W2340414627A5006101210 @default.
- W2340414627 hasAuthorship W2340414627A5017367541 @default.
- W2340414627 hasAuthorship W2340414627A5031390646 @default.
- W2340414627 hasAuthorship W2340414627A5034392417 @default.
- W2340414627 hasAuthorship W2340414627A5037781025 @default.
- W2340414627 hasAuthorship W2340414627A5045462759 @default.
- W2340414627 hasAuthorship W2340414627A5048060803 @default.
- W2340414627 hasAuthorship W2340414627A5058702476 @default.
- W2340414627 hasAuthorship W2340414627A5063957223 @default.
- W2340414627 hasAuthorship W2340414627A5087316611 @default.
- W2340414627 hasConcept C121608353 @default.
- W2340414627 hasConcept C126322002 @default.
- W2340414627 hasConcept C126894567 @default.
- W2340414627 hasConcept C141071460 @default.
- W2340414627 hasConcept C143998085 @default.
- W2340414627 hasConcept C203092338 @default.
- W2340414627 hasConcept C2776611710 @default.
- W2340414627 hasConcept C2776694085 @default.
- W2340414627 hasConcept C2777292972 @default.
- W2340414627 hasConcept C2777511904 @default.
- W2340414627 hasConcept C2778239845 @default.
- W2340414627 hasConcept C2780474809 @default.
- W2340414627 hasConcept C2780775027 @default.
- W2340414627 hasConcept C2781451048 @default.
- W2340414627 hasConcept C31760486 @default.
- W2340414627 hasConcept C509974204 @default.
- W2340414627 hasConcept C530470458 @default.
- W2340414627 hasConcept C535046627 @default.
- W2340414627 hasConcept C71924100 @default.
- W2340414627 hasConceptScore W2340414627C121608353 @default.
- W2340414627 hasConceptScore W2340414627C126322002 @default.
- W2340414627 hasConceptScore W2340414627C126894567 @default.
- W2340414627 hasConceptScore W2340414627C141071460 @default.
- W2340414627 hasConceptScore W2340414627C143998085 @default.
- W2340414627 hasConceptScore W2340414627C203092338 @default.
- W2340414627 hasConceptScore W2340414627C2776611710 @default.
- W2340414627 hasConceptScore W2340414627C2776694085 @default.
- W2340414627 hasConceptScore W2340414627C2777292972 @default.
- W2340414627 hasConceptScore W2340414627C2777511904 @default.
- W2340414627 hasConceptScore W2340414627C2778239845 @default.
- W2340414627 hasConceptScore W2340414627C2780474809 @default.
- W2340414627 hasConceptScore W2340414627C2780775027 @default.
- W2340414627 hasConceptScore W2340414627C2781451048 @default.
- W2340414627 hasConceptScore W2340414627C31760486 @default.
- W2340414627 hasConceptScore W2340414627C509974204 @default.
- W2340414627 hasConceptScore W2340414627C530470458 @default.
- W2340414627 hasConceptScore W2340414627C535046627 @default.
- W2340414627 hasConceptScore W2340414627C71924100 @default.
- W2340414627 hasIssue "18_suppl" @default.
- W2340414627 hasLocation W23404146271 @default.
- W2340414627 hasOpenAccess W2340414627 @default.
- W2340414627 hasPrimaryLocation W23404146271 @default.
- W2340414627 hasRelatedWork W1502181122 @default.
- W2340414627 hasRelatedWork W1982849070 @default.
- W2340414627 hasRelatedWork W2006385338 @default.
- W2340414627 hasRelatedWork W2053778437 @default.
- W2340414627 hasRelatedWork W2063171892 @default.
- W2340414627 hasRelatedWork W2100029565 @default.
- W2340414627 hasRelatedWork W2380099415 @default.
- W2340414627 hasRelatedWork W2415963934 @default.
- W2340414627 hasRelatedWork W4250038123 @default.
- W2340414627 hasRelatedWork W84951532 @default.
- W2340414627 hasVolume "24" @default.
- W2340414627 isParatext "false" @default.
- W2340414627 isRetracted "false" @default.
- W2340414627 magId "2340414627" @default.
- W2340414627 workType "article" @default.